50,762 AnaptysBio, Inc. $ANAB Shares Bought by Moody Aldrich Partners LLC

Key Points

• Moody Aldrich Partners increased its AnaptysBio stake by 164.1% in the third quarter, buying 50,762 additional shares for a total holding of 81,688 shares valued at approximately $4.1 million.
• Several major institutions also built positions in AnaptysBio, including BlackRock, Palo Alto Investors, Bank of America and HSBC, while insider ownership stood at 31.5%; a director separately sold 5,000 shares under a Rule 10b5-1 plan.
• Analysts hold a consensus “Moderate Buy” rating with an average $77.79 price target, although individual views range from “Sell” to “Outperform.” Shares opened at $50.50, and the company recently exceeded quarterly earnings and revenue expectations.

Moody Aldrich Partners LLC raised its position in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 164.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 81,688 shares of the biotechnology company's stock after purchasing an additional 50,762 shares during the period. Moody Aldrich Partners LLC owned 0.27% of AnaptysBio worth $4,106,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. BlackRock Inc. purchased a new stake in shares of AnaptysBio during the 2nd quarter worth $124,473,000. Palo Alto Investors LP purchased a new position in AnaptysBio in the second quarter valued at $40,735,508. Affinity Asset Advisors LLC raised its stake in AnaptysBio by 111.4% in the first quarter. Affinity Asset Advisors LLC now owns 940,000 shares of the biotechnology company's stock valued at $52,132,000 after buying an additional 495,308 shares in the last quarter. Bank of America Corp DE acquired a new stake in AnaptysBio in the second quarter valued at $28,202,000. Finally, Hsbc Holdings PLC acquired a new stake in AnaptysBio in the second quarter valued at $14,928,000.

Insiders Place Their Bets

In related news, Director Hollings Renton sold 5,000 shares of AnaptysBio stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $49.87, for a total value of $249,350.00. Following the transaction, the director directly owned 10,995 shares in the company, valued at $548,320.65. This trade represents a 31.26% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 31.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

ANAB has been the subject of several analyst reports. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of AnaptysBio in a research report on Friday, August 7th. Wolfe Research restated an "outperform" rating and issued a $78.00 price objective on shares of AnaptysBio in a research note on Monday, August 31st. JPMorgan Chase & Co. dropped their price objective on AnaptysBio from $70.00 to $60.00 and set an "overweight" rating on the stock in a report on Wednesday, September 30th. Scotiabank lowered AnaptysBio to a "hold" rating and set a $70.00 price objective on the stock. in a report on Tuesday, August 25th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of AnaptysBio in a research report on Tuesday, September 22nd. Thirteen research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $77.79.

AnaptysBio Stock Performance

Shares of AnaptysBio stock opened at $50.50 on Thursday. The company has a market capitalization of $1.51 billion, a P/E ratio of 9.40 and a beta of 0.76. AnaptysBio, Inc. has a 1 year low of $20.18 and a 1 year high of $72.36. The company's fifty day moving average is $52.14 and its two-hundred day moving average is $56.29.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its earnings results on Monday, September 21st. The biotechnology company reported $5.11 EPS for the quarter, beating analysts' consensus estimates of ($0.46) by $5.57. AnaptysBio had a net margin of 82.37% and a return on equity of 112.00%. The business had revenue of $27.49 million during the quarter, compared to analysts' expectations of $14.06 million. During the same period in the prior year, the company earned ($1.30) earnings per share. As a group, equities analysts expect that AnaptysBio, Inc. will post -1.30 earnings per share for the current year.

AnaptysBio Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for immune-mediated diseases. The company uses its proprietary antibody discovery and engineering platform to identify therapeutics designed to modulate immune-system pathways involved in inflammation and autoimmune disorders.

AnaptysBio's pipeline has included rosnilimab, an investigational antibody designed to activate the PD-1 immune checkpoint pathway, and imsidolimab, an investigational antibody targeting the interleukin-36 receptor.

Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio, Inc. (NASDAQ:ANAB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.